COMFORT-1 and joy for Incyte/Novartis' JAK inhibitor
This article was originally published in Scrip
Incyte will file for approval of its leading oral dual JAK inhibitor INCB18424 (ruxolitinib/INC424) for myelofibrosis in the US in the second quarter of 2011, based on highly promising results from its first Phase III study, COMFORT-1. It hopes the drug will become the first FDA-approved drug to treat the debilitating symptoms of the disease.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.